Replies to post #19323 on Radient Pharmaceuticals Corporation fka RXPC

[blackpantherz]

CIT uses two genes in combination to build the body's immune system and to destroy cancer cells. The GM-CSF gene alters the tumor to activate tumor-specific T-cells within the immune system, while the B7-2 gene enters the tumor to stimulate larger and stronger T-cells to fight the cancer. This is a variation of the traditional concept of gene therapy, which seeks to replace damaged or abnormal genes with healthy ones. Replacing defective genes in cancer cells has proven impractical because of the number of genes involved.

CIT has undergone successful Phase I clinical trials in skin and brain cancer patients and was shown to be 100 percent effective in a humanized mouse model at the University of Alberta, Canada. Publications that have reported on this therapy include "Human Gene Therapy" and "Neurosurgery."

"Potential products in the multi-billion dollar global cancer market are being sought by major pharmaceutical and other companies and we believe our therapy has significant, important features to offer to these firms," said Gary Dreher, AMDL President and CEO.